{"schema_version":"secwatch.filing_event.v1","accession":"0001531048-23-000034","form_type":"8-K","ticker":null,"cik":"0001531048","company_name":"Inari Medical, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.399758+00:00","generated_at":"2026-06-08T02:21:31.291321+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inari Medical closes $250M acquisition of LimFlow for CLTI limb salvage","bullets":["Paid ~$238.4M at closing after adjustments; total upfront $250M cash from existing resources.","Up to $165M in contingent milestones payable between 2025-2027 based on commercial/reimbursement goals.","LimFlow is a pioneer in limb salvage for chronic limb-threatening ischemia (CLTI).","Financial statements and pro forma results to be filed within 71 days of this report."],"urls":{"canonical":"https://secwatch.observer/filing/0001531048-23-000034","json":"https://secwatch.observer/filing/0001531048-23-000034.json","markdown":"https://secwatch.observer/filing/0001531048-23-000034.md","text":"https://secwatch.observer/filing/0001531048-23-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531048/000153104823000034/0001531048-23-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531048/000153104823000034/nari-20231115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:21:31.291321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e723741236144b1f9e3487d83d17392d73e019d","claim":"Inari Medical, Inc. completed an acquisition involving LimFlow S.A. for approximately $238.4 million (closed 2023-11-15).","evidence_excerpt":"15, 2023, the Company announced that it closed its acquisition of LimFlow (the “ Closing ”). Pursuant to the terms of the Purchase Agreement, the Company delivered approximately $238.4 million to the Sellers at the Closing, after accounting for working capital, indebtedness, cash and transaction expenses. The Company funded the transaction from its existing cash","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531048/000153104823000034/0001531048-23-000034-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"LimFlow S.A."},{"label":"Consideration","value":"approximately $238.4 million"},{"label":"Closing","value":"2023-11-15"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}